A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin
Abstract Background The main differences in cases of sudden elevation of hepatic enzyme levels during immunochemotherapy are the reactivation of the hepatitis B virus or drug‐induced liver injury. Here, we report a case of acute liver injury caused by the hepatitis E virus (HEV) during chemotherapy...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1957 |
| _version_ | 1827339342182350848 |
|---|---|
| author | Seiya Hashimoto Hirofumi Fukuda Kohei Takeda Keiichi Uchida Fumiaki Sanuki Takashi Akiyama Eisei Kondo Hideho Wada |
| author_facet | Seiya Hashimoto Hirofumi Fukuda Kohei Takeda Keiichi Uchida Fumiaki Sanuki Takashi Akiyama Eisei Kondo Hideho Wada |
| author_sort | Seiya Hashimoto |
| collection | DOAJ |
| description | Abstract Background The main differences in cases of sudden elevation of hepatic enzyme levels during immunochemotherapy are the reactivation of the hepatitis B virus or drug‐induced liver injury. Here, we report a case of acute liver injury caused by the hepatitis E virus (HEV) during chemotherapy for malignant lymphoma, wherein the patient was successfully treated for the hepatitis and resumed chemotherapy to completion. Case A 57‐year‐old woman visited her local doctor because she felt lightweight and tired. The patient underwent lower gastrointestinal endoscopy and was diagnosed with a malignant lymphoma of the small intestine (diffuse large B‐cell lymphoma). The patient had a history of oral consumption of undercooked pork liver to improve anemia and was diagnosed with acute hepatitis E. Conclusion This report highlights the successful treatment of HEV infection in a patient undergoing immunosuppressive therapy for malignant lymphomas. A novel aspect of this study is the safe and effective use of ribavirin, an antiviral medication, along with continued chemotherapy, which resulted in sustained virological response (SVR) and the completion of the planned chemotherapy regimen. This report also provides new insights into the management of HEV infections in immunosuppressed patients undergoing chemotherapy and emphasizes the importance of considering HEV as a potential cause of acute liver injury in such cases. The successful use of ribavirin along with continued chemotherapy offers a promising treatment strategy for clinicians to consider in similar scenarios. |
| first_indexed | 2024-03-07T19:57:59Z |
| format | Article |
| id | doaj.art-567cdf4be41e4e599912aa2739c341ae |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-03-07T19:57:59Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-567cdf4be41e4e599912aa2739c341ae2024-02-28T13:54:58ZengWileyCancer Reports2573-83482024-02-0172n/an/a10.1002/cnr2.1957A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirinSeiya Hashimoto0Hirofumi Fukuda1Kohei Takeda2Keiichi Uchida3Fumiaki Sanuki4Takashi Akiyama5Eisei Kondo6Hideho Wada7Department of Hematology Kawasaki Medical School Kurashiki JapanDepartment of Hematology Kawasaki Medical School Kurashiki JapanDepartment of Hematology Kawasaki Medical School Kurashiki JapanDepartment of Hematology Kawasaki Medical School Kurashiki JapanDepartment of Pathology Kawasaki Medical School Kurashiki JapanDepartment of Pathology Kawasaki Medical School Kurashiki JapanDepartment of Hematology Kawasaki Medical School Kurashiki JapanDepartment of Hematology Kawasaki Medical School Kurashiki JapanAbstract Background The main differences in cases of sudden elevation of hepatic enzyme levels during immunochemotherapy are the reactivation of the hepatitis B virus or drug‐induced liver injury. Here, we report a case of acute liver injury caused by the hepatitis E virus (HEV) during chemotherapy for malignant lymphoma, wherein the patient was successfully treated for the hepatitis and resumed chemotherapy to completion. Case A 57‐year‐old woman visited her local doctor because she felt lightweight and tired. The patient underwent lower gastrointestinal endoscopy and was diagnosed with a malignant lymphoma of the small intestine (diffuse large B‐cell lymphoma). The patient had a history of oral consumption of undercooked pork liver to improve anemia and was diagnosed with acute hepatitis E. Conclusion This report highlights the successful treatment of HEV infection in a patient undergoing immunosuppressive therapy for malignant lymphomas. A novel aspect of this study is the safe and effective use of ribavirin, an antiviral medication, along with continued chemotherapy, which resulted in sustained virological response (SVR) and the completion of the planned chemotherapy regimen. This report also provides new insights into the management of HEV infections in immunosuppressed patients undergoing chemotherapy and emphasizes the importance of considering HEV as a potential cause of acute liver injury in such cases. The successful use of ribavirin along with continued chemotherapy offers a promising treatment strategy for clinicians to consider in similar scenarios.https://doi.org/10.1002/cnr2.1957chemotherapyhepatitis E virusribavirin |
| spellingShingle | Seiya Hashimoto Hirofumi Fukuda Kohei Takeda Keiichi Uchida Fumiaki Sanuki Takashi Akiyama Eisei Kondo Hideho Wada A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin Cancer Reports chemotherapy hepatitis E virus ribavirin |
| title | A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin |
| title_full | A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin |
| title_fullStr | A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin |
| title_full_unstemmed | A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin |
| title_short | A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin |
| title_sort | case of hepatitis e that developed during chemotherapy for malignant lymphoma and responded to ribavirin |
| topic | chemotherapy hepatitis E virus ribavirin |
| url | https://doi.org/10.1002/cnr2.1957 |
| work_keys_str_mv | AT seiyahashimoto acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT hirofumifukuda acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT koheitakeda acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT keiichiuchida acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT fumiakisanuki acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT takashiakiyama acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT eiseikondo acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT hidehowada acaseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT seiyahashimoto caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT hirofumifukuda caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT koheitakeda caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT keiichiuchida caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT fumiakisanuki caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT takashiakiyama caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT eiseikondo caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin AT hidehowada caseofhepatitisethatdevelopedduringchemotherapyformalignantlymphomaandrespondedtoribavirin |